2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI)

Gregory Y. H. Lip*, Jean-Phillippe Collet, Michael Haude, Robert Byrne, Eugene H. Chung, Laurent Fauchier, Sigrun Halvorsen, Dennis Lau, Nestor Lopez-Cabanillas, Maddalena Lettino, Francisco Marin, Israel Obel, Andrea Rubboli, Robert F. Storey, Marco Valgimigli, Kurt Huber, Tatjana Potpara, Carina Blomstrom Lundqvist, Harry Crijns, Jan SteffelHein Heidbuchel, Goran Stankovic, Juhani Airaksinen, Jurrien M. Ten Berg, Davide Capodanno, Stefan James, Hector Bueno, Joao Morais, Dirk Sibbing, Bianca Rocca, Ming-Hsiung Hsieh, Nazem Akoum, Deborah J. Lockwood, Jorge Rafael Gomez Flores, Ronald Jardine, ESC Scientific Document Group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

182 Citations (Web of Science)

Abstract

In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Since publication of this document, additional data from observational cohorts, randomized controlled trials, and percutaneous interventions as well as new guidelines have been published. Moreover, new drugs and devices/interventions are also available, with an increasing evidence base. The approach to managing AF has also evolved towards a more integrated or holistic approach. In recognizing these advances since the last consensus document, EHRA, WG Thrombosis, EAPCI, and ACCA, with additional contributions from HRS, APHRS, Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), proposed a focused update, to include the new data, with the remit of comprehensively reviewing the available evidence and publishing a focused update consensus document on the management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions, and providing up-to-date consensus recommendations for use in clinical practice.

Original languageEnglish
Pages (from-to)192-193
Number of pages27
JournalEP Europace
Volume21
Issue number2
DOIs
Publication statusPublished - Feb 2019

Keywords

  • European Heart Rhythm Association
  • Consensus document
  • Position paper
  • Atrial fibrillation
  • Acute coronary syndrome
  • Coronary artery disease
  • Myocardial infarction
  • Percutaneous coronary intervention
  • Stent
  • Antithrombotic therapy
  • Antiplatelet agents
  • Anticoagulation
  • Vitamin K antagonists
  • Non-vitamin K antagonist oral anticoagulants
  • Low molecular weight heparin
  • Parenteral anticoagulants
  • Left atrial appendage occlusion
  • Stroke
  • Thromboembolism
  • Thrombosis
  • Bleeding
  • AORTIC-VALVE IMPLANTATION
  • ACUTE MYOCARDIAL-INFARCTION
  • DUAL ANTIPLATELET THERAPY
  • BLEEDING RISK SCORES
  • VITAMIN-K ANTAGONIST
  • ST-SEGMENT ELEVATION
  • HAS-BLED SCORES
  • UNINTERRUPTED ORAL ANTICOAGULATION
  • ELUTING STENT IMPLANTATION
  • BARE-METAL STENTS

Cite this